Regulatory T cells (Tregs) are essential for maintaining immune balance and self-tolerance, acting as key suppressors of excessive immune activation. By inhibiting T cell proliferation and cytokine release, they prevent autoimmune reactions and shape immune dynamics within the tumor microenvironment.
Our platform integrates tumor organoids, cytotoxic T cells (CD8+), and regulatory T cells (Tregs) to assess the efficacy of anticancer agents, enabling a deeper understanding of how immune suppression influences therapeutic outcomes.
Price | 7500€+ |
Organism | Human |
Product Type | Organoid + T cell + Regulatory T cell |
Tissue | Adaptive |
Disease | – |
Applications
Cancer Organoid
Colorectal Cancer
Non-Small Cell Lung Cancer
Pancreatic Cancer
Breast Cancer
Cholangiocarcinoma
Gastric Cancer
Ovarian Cancer
With the global rise of K-beauty, the cosmetics industry continues to grow steadily. Since the ban on animal testing for cosmetics in Korea in 2017, various alternative testing methods have...
Traditional microscopy methods often require fluorescent labeling to analyze cellular structures, which can be time-consuming and invasive. In contrast, our HT-X1 system allows for high-resolution visualization of cellular morphology without...
Traditional protein analysis has primarily focused on quantifying expression levels within tissue samples. However, recent advances in spatial analysis techniques have shifted attention toward evaluating not only expression levels, but...
We conducted a study focused on identifying disease-related markers using patient-derived tissue samples. However, traditional methods limited our ability to analyze multiple candidate markers simultaneously, and the limited availability of...
A co-culture system integrating regulatory T cells (Tregs), effector T cells, and cancer organoids enables the evaluation of compounds that influence Treg activity. This approach provides a powerful platform to assess drugs that modulate immune suppression within the tumor microenvironment.
We developed tumor organoids incorporating key elements of the tumor microenvironment to serve as a platform for drug evaluation. To achieve this, tumor organoids, cytotoxic T cells, and regulatory T cells were co-cultured at defined ratios.
T cells were first activated from PBMCs, then cytotoxic and regulatory subsets were isolated, cultured, and quantified separately. After establishing the co-culture system, we evaluated the efficacy of immuno-oncology agents under controlled conditions.
R1 / T-cell
R1 / T-cell
Cell nr | Gated % | |
|---|---|---|
CD8+ | 47,600 | – |
All Events / Treg
CD4+CD5+ / Treg
Cell nr | Gated % | |
|---|---|---|
CD8+ CD25+ FoxP3 | 7,500 | – |
Regulatory T cells (Tregs) are a specialized subset of CD4+ T cells that maintain immune homeostasis by suppressing excessive immune activation. They play a critical role in preventing autoimmunity and modulating the immune response within the tumor microenvironment.
In many tumors, Tregs accumulate in the microenvironment and suppress cytotoxic immune responses, enabling tumor immune evasion. Studying Treg function and dynamics helps researchers understand mechanisms of immune suppression and develop strategies to enhance anti-tumor immunity.
Lambda Biologics’ Regulatory T cell models are derived and characterized for functional activity and immune-suppressive capacity. When integrated with patient-derived organoids or immune co-culture systems, they offer a physiologically relevant platform to study immune regulation and evaluate immunomodulatory therapies.
